Anna F. Farago, MD, PhD
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK
gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.UPDATE 11/26/2018: FDA Approves Larotrectinib for NTRK+ Cancers
The NDA is based on findings from patients with TRK-positive tumors enrolled across phase I or II clinical trials. In results published in the New England Journal of Medicine
) in February 2018, larotrectinib induced an objective response rate of 75% (95% CI, 61-85) by independent review and 80% (95% CI, 67-90) by investigator assessment in 55 evaluable patients. Per the independent assessment, there were 7 (13%) complete responses, 34 (62%) partial responses, and 5 (9%) patients with stable disease.1
At 1 year, 71% of responses were ongoing. More than half (55%) of patients remained progression-free at 1 year. The median duration of response had not been reached after a median follow-up of 8.3 months. The same was true for median progression-free survival after a median follow-up of 9.9 months.
Under the Prescription Drug User Fee Act, the FDA is scheduled to make its decision on the NDA by November 26, 2018.
“TRK fusion cancer is not limited to any organ or site of the body and occurs in both adults and children,” Scott Fields, MD, senior vice president and head of Oncology Development at Bayer’s Pharmaceutical Division, said in a statement. “The priority review designation for larotrectinib may help bring this treatment option to patients, facing a high unmet medical need, as soon as possible.”
In a recent interview with OncLive
, Anna Farago, MD, PhD, a coinvestigator on the pivotal phase I/II research, commented on the potential implications of larotrectinib receiving an FDA approval.
“In some cancer types, TRK
fusions are very rare. I am primarily a thoracic oncologist and, in lung cancer, these fusions occur at a frequency of well under 1%. In less common cancer types, they are more common. For example, these are fusions that are commonly seen in pediatric fibrosarcoma. The total number of patients who may benefit is slightly difficult to predict at this point, but for patients whose cancer has a TRK
fusion, these drugs can be tremendously effective,” said Farago, an instructor of Medicine at Harvard Medical School, and assistant in Medicine in the Division of Hematology/Oncology at Massachusetts General Hospital.
“We see a very high response rate of 75% by central review and a median progression-free survival that was not yet reached at a median follow-up of 9.4 months. Like other targeted therapies where you find the right drug for the right oncogenic driver, this drug will be tremendously attractive for those patients with TRK fusions,” Farago added.
data included an additional 3 months of patient follow-up to data presented at the 2017 ASCO Annual Meeting.2 The data presented at ASCO came from the first 55 consecutively enrolled adult and pediatric patients with TRK fusion cancers from across a phase I adult trial, the phase II NAVIGATE trial, and the phase I/II SCOUT pediatric trial. The data cutoff for the NEJM findings was July 17, 2017.
TRK fusion–positive adult and pediatric patients with advanced solid tumors representing 17 unique cancer types were enrolled across the 3 phase I/II clinical trials. The breakdown by tumor type included salivary gland tumor (n = 12), other soft-tissue sarcoma (n = 11), infantile fibrosarcoma (n = 7), thyroid tumor (n = 5), colon cancer (n = 4), lung cancer (n = 4), melanoma (n = 4), GIST (n = 3), cholangiocarcinoma (n = 2), appendix tumor (n = 1), breast cancer (n = 1), and pancreatic cancer (n = 1).
The median age of patients was 45 years (range, 0.3-76.0), with 56% of patients ≥40 years of age. A third of patients (35%) had received ≥3 prior systemic chemotherapies. Twenty-four patients had an ECOG performance status of 0, 27 had a status of 1, and 4 had a status of 2. Patients were assigned to 100 mg of larotrectinib twice daily.
Investigators did not notice a trend toward better results in one tumor type versus another with larotrectinib. Additionally, outcomes appeared similar regardless of the age of patients or the type of NTRK alteration (1, 2, or 3) or fusion partner.
Most patients (93%) experienced grade 1 or 2 adverse events (AEs). There were no grade 4 AEs related to treatment and the most common treatment-related grade 3 AEs were increased ALT or AST (5%), anemia (2%), decreased neutrophil count (2%), nausea (2%), and dizziness (2%).
The most common grade 3 AEs (≥5%) regardless of attribution were anemia (11%), increased ALT or AST (7%), decreased neutrophil count (7%), and increased body weight (7%).
gene fusions are genetic alterations that appear across a wide range of tumors—including breast and colorectal cancer, infantile fibrosarcoma, lung cancer, melanoma, and various sarcomas—and lead to uncontrolled TRK signaling and tumor growth. Such fusions are rare, but they are expressed in dozens of adult and pediatric tumor types. To date, researchers have identified more than 50 different partner genes that fuse with 1 of 3 TRK genes (NTRK 1, 2, and 3).
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018; 378:731-739. doi: 10.1056/NEJMoa1714448.
- Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35 (suppl; abstr LBA2501).